<DOC>
	<DOC>NCT01455428</DOC>
	<brief_summary>To prove pregabalin is effective in relieving pain compared with placebo in subjects with postherpetic neuralgia (PHN).</brief_summary>
	<brief_title>Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Male or female Chinese subjects, ages ≥18 at screening Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia (PHN). Subjects must have pain present for ﹥3 months after healing of the acute herpes zoster skin rash At screening (V1), subjects must have a score ≥40mm on the 100mm visual analog scale (VAS) of the Short FormMcGill Pain Questionnaire (SFMPQ, see Appendix 3) At randomization (V2), subjects must have a score ≥40mm on the 100mm visual analog scale (VAS) of the Short FormMcGill Pain Questionnaire (SFMPQ, see Appendix 3) At randomization (V2), subjects must have completed at least 5 daily pain diaries (DPRS, see Appendix 2) and have an average daily pain score ≥4 over the past 7 days Subjects who demonstrate a high response to placebo, with 30% decrease on the Pain Visual Analog Scale (VAS) at randomization as compared to screening Subjects who have a high variability in pain scores during the 1 week screening period, with any difference between two scores ﹥3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Pregabalin</keyword>
	<keyword>Postherpetic Neuralgia ( PHN )</keyword>
</DOC>